These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 23245571)

  • 1. New structure-activity relationship studies in a series of N,N-bis(cyclohexanol)amine aryl esters as potent reversers of P-glycoprotein-mediated multidrug resistance (MDR).
    Orlandi F; Coronnello M; Bellucci C; Dei S; Guandalini L; Manetti D; Martelli C; Romanelli MN; Scapecchi S; Salerno M; Menif H; Bello I; Mini E; Teodori E
    Bioorg Med Chem; 2013 Jan; 21(2):456-65. PubMed ID: 23245571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-activity relationships studies in a series of N,N-bis(alkanol)amine aryl esters as P-glycoprotein (Pgp) dependent multidrug resistance (MDR) inhibitors.
    Martelli C; Coronnello M; Dei S; Manetti D; Orlandi F; Scapecchi S; Novella Romanelli M; Salerno M; Mini E; Teodori E
    J Med Chem; 2010 Feb; 53(4):1755-62. PubMed ID: 20104851
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multidrug resistance (MDR) reversers: High activity and efficacy in a series of asymmetrical N,N-bis(alkanol)amine aryl esters.
    Dei S; Coronnello M; Floriddia E; Bartolucci G; Bellucci C; Guandalini L; Manetti D; Romanelli MN; Salerno M; Bello I; Mini E; Teodori E
    Eur J Med Chem; 2014 Nov; 87():398-412. PubMed ID: 25282263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N-alkanol-N-cyclohexanol amine aryl esters: Multidrug resistance (MDR) reversing agents with high potency and efficacy.
    Teodori E; Dei S; Coronnello M; Floriddia E; Bartolucci G; Manetti D; Romanelli MN; Santo Domingo Porqueras D; Salerno M
    Eur J Med Chem; 2017 Feb; 127():586-598. PubMed ID: 28113128
    [TBL] [Abstract][Full Text] [Related]  

  • 5. N,N-bis(cyclohexanol)amine aryl esters: a new class of highly potent transporter-dependent multidrug resistance inhibitors.
    Martelli C; Alderighi D; Coronnello M; Dei S; Frosini M; Le Bozec B; Manetti D; Neri A; Romanelli MN; Salerno M; Scapecchi S; Mini E; Sgaragli G; Teodori E
    J Med Chem; 2009 Feb; 52(3):807-17. PubMed ID: 19140665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of P-glycoprotein-mediated Multidrug Resistance (MDR) by N,N-bis(cyclohexanol)amine aryl esters: further restriction of molecular flexibility maintains high potency and efficacy.
    Martelli C; Dei S; Lambert C; Manetti D; Orlandi F; Romanelli MN; Scapecchi S; Salerno M; Teodori E
    Bioorg Med Chem Lett; 2011 Jan; 21(1):106-9. PubMed ID: 21145739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulation of the spacer in N,N-bis(alkanol)amine aryl ester heterodimers led to the discovery of a series of highly potent P-glycoprotein-based multidrug resistance (MDR) modulators.
    Dei S; Braconi L; Trezza A; Menicatti M; Contino M; Coronnello M; Chiaramonte N; Manetti D; Perrone MG; Romanelli MN; Udomtanakunchai C; Colabufo NA; Bartolucci G; Spiga O; Salerno M; Teodori E
    Eur J Med Chem; 2019 Jun; 172():71-94. PubMed ID: 30947123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isomeric N,N-bis(cyclohexanol)amine aryl esters: the discovery of a new class of highly potent P-glycoprotein (Pgp)-dependent multidrug resistance (MDR) inhibitors.
    Teodori E; Martelli C; Salerno M; Darghal N; Dei S; Garnier-Suillerot A; Gualtieri F; Manetti D; Scapecchi S; Romanelli MN
    J Med Chem; 2007 Feb; 50(4):599-602. PubMed ID: 17256837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design and synthesis of new potent N,N-bis(arylalkyl)piperazine derivatives as multidrug resistance (MDR) reversing agents.
    Dei S; Coronnello M; Bartolucci G; Manetti D; Romanelli MN; Udomtanakunchai C; Salerno M; Teodori E
    Eur J Med Chem; 2018 Mar; 147():7-20. PubMed ID: 29421572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design and synthesis of aminoester heterodimers containing flavone or chromone moieties as modulators of P-glycoprotein-based multidrug resistance (MDR).
    Dei S; Romanelli MN; Manetti D; Chiaramonte N; Coronnello M; Salerno M; Teodori E
    Bioorg Med Chem; 2018 Jan; 26(1):50-64. PubMed ID: 29162309
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis and biological evaluation of stereo- and regioisomers of amino aryl esters as multidrug resistance (MDR) reversers.
    Teodori E; Contino M; Riganti C; Bartolucci G; Braconi L; Manetti D; Romanelli MN; Trezza A; Athanasios A; Spiga O; Perrone MG; Giampietro R; Gazzano E; Salerno M; Colabufo NA; Dei S
    Eur J Med Chem; 2019 Nov; 182():111655. PubMed ID: 31494468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. N,N-bis(cyclohexanol)amine aryl esters: the discovery of a new class of highly potent inhibitors of transporter-dependent multidrug resistance (MDR).
    Teodori E; Dei S; Martelli C; Scapecchi S
    Curr Top Med Chem; 2010; 10(17):1715-31. PubMed ID: 20645921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. N,N-bis(cyclohexanol)amine aryl esters inhibit P-glycoprotein as transport substrates.
    Neri A; Frosini M; Valoti M; Cacace MG; Teodori E; Sgaragli G
    Biochem Pharmacol; 2011 Dec; 82(12):1822-31. PubMed ID: 21920352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual P-Glycoprotein and CA XII Inhibitors: A New Strategy to Reverse the P-gp Mediated Multidrug Resistance (MDR) in Cancer Cells.
    Teodori E; Braconi L; Bua S; Lapucci A; Bartolucci G; Manetti D; Romanelli MN; Dei S; Supuran CT; Coronnello M
    Molecules; 2020 Apr; 25(7):. PubMed ID: 32290281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Substituted tetrahydroisoquinoline compound B3 inhibited P-glycoprotein-mediated multidrug resistance in-vitro and in-vivo.
    Fang W; Li Y; Cai Y; Kang K; Yan F; Liu G; Huang W
    J Pharm Pharmacol; 2007 Dec; 59(12):1649-55. PubMed ID: 18053326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential effects of peroxisome proliferator-activated receptor agonists on doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells.
    Yousefi B; Samadi N; Baradaran B; Rameshknia V; Shafiei-Irannejad V; Majidinia M; Targhaze N; Zarghami N
    Cell Mol Biol (Noisy-le-grand); 2015 Dec; 61(8):118-22. PubMed ID: 26718439
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis and evaluation of novel triazole core based P-glycoprotein-mediated multidrug resistance reversal agents.
    Jiao L; Qiu Q; Liu B; Zhao T; Huang W; Qian H
    Bioorg Med Chem; 2014 Dec; 22(24):6857-66. PubMed ID: 25464884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of P-glycoprotein-mediated multidrug resistance in K562 leukemic cells by indole-3-carbinol.
    Arora A; Seth K; Kalra N; Shukla Y
    Toxicol Appl Pharmacol; 2005 Feb; 202(3):237-43. PubMed ID: 15667829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CJY, an isoflavone, reverses P-glycoprotein-mediated multidrug-resistance in doxorubicin-resistant human myelogenous leukaemia (K562/DOX) cells.
    Ji BS; He L
    J Pharm Pharmacol; 2007 Jul; 59(7):1011-5. PubMed ID: 17637197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reversal of p-glycoprotein-mediated multidrug resistance by macrocyclic bisbibenzyl derivatives in adriamycin-resistant human myelogenous leukemia (K562/A02) cells.
    Li X; Sun B; Zhu CJ; Yuan HQ; Shi YQ; Gao J; Li SJ; Lou HX
    Toxicol In Vitro; 2009 Feb; 23(1):29-36. PubMed ID: 18938236
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.